These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 24326545)

  • 21. Interleukin 21 as a new possible player in pemphigus: Is it a suitable target?
    Tavakolpour S
    Int Immunopharmacol; 2016 May; 34():139-145. PubMed ID: 26945832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a potent anti-IL-15 antibody with opposing mechanisms of action in vitro and in vivo.
    Finch DK; Midha A; Buchanan CL; Cochrane D; Craggs RI; Cruwys S; Grahames C; Kolbeck R; Lowe DC; Maltby J; Pattison DV; Vousden KA; Ward A; Sleeman MA; Mallinder PR
    Br J Pharmacol; 2011 Jan; 162(2):480-90. PubMed ID: 20942844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
    Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
    Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Homeostasis of IL-15 dependent lymphocyte subsets in the liver.
    Cepero-Donates Y; Rakotoarivelo V; Mayhue M; Ma A; Chen YG; Ramanathan S
    Cytokine; 2016 Jun; 82():95-101. PubMed ID: 26778709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells.
    Dubois S; Mariner J; Waldmann TA; Tagaya Y
    Immunity; 2002 Nov; 17(5):537-47. PubMed ID: 12433361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia.
    Morris JC; Janik JE; White JD; Fleisher TA; Brown M; Tsudo M; Goldman CK; Bryant B; Petrus M; Top L; Lee CC; Gao W; Waldmann TA
    Proc Natl Acad Sci U S A; 2006 Jan; 103(2):401-6. PubMed ID: 16387851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.
    Salman A; Sarac G; Ergun T
    Dermatol Online J; 2017 Jul; 23(7):. PubMed ID: 29469706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
    Wu Z; Xu Y
    J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No requirement of trans presentations of IL-15 for human CD8 T cell proliferation.
    Ota N; Takase M; Uchiyama H; Olsen SK; Kanagawa O
    J Immunol; 2010 Nov; 185(10):6041-8. PubMed ID: 20926799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Alopecia Areata With Tofacitinib.
    Ibrahim O; Bayart CB; Hogan S; Piliang M; Bergfeld WF
    JAMA Dermatol; 2017 Jun; 153(6):600-602. PubMed ID: 28355451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A programmed switch from IL-15- to IL-2-dependent activation in human NK cells.
    Pillet AH; Bugault F; Thèze J; Chakrabarti LA; Rose T
    J Immunol; 2009 May; 182(10):6267-77. PubMed ID: 19414780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IFN-α primes T- and NK-cells for IL-15-mediated signaling and cytotoxicity.
    Hansen ML; Woetmann A; Krejsgaard T; Kopp KL; Søkilde R; Litman T; Straten PT; Geisler C; Wasik MA; Odum N; Eriksen KW
    Mol Immunol; 2011 Sep; 48(15-16):2087-93. PubMed ID: 21813181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The anti-inflammatory potential of cefazolin as common gamma chain cytokine inhibitor.
    Żyżyńska-Granica B; Trzaskowski B; Dutkiewicz M; Zegrocka-Stendel O; Machcińska M; Bocian K; Kowalewska M; Koziak K
    Sci Rep; 2020 Feb; 10(1):2886. PubMed ID: 32076052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tofacitinib in kidney transplantation.
    Wojciechowski D; Vincenti F
    Expert Opin Investig Drugs; 2013 Sep; 22(9):1193-9. PubMed ID: 23841583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein-kinase inhibitors: A new treatment pathway for autoimmune and inflammatory diseases?
    Hernández-Flórez D; Valor L
    Reumatol Clin; 2016; 12(2):91-9. PubMed ID: 26283525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer.
    Waldmann TA; Miljkovic MD; Conlon KC
    J Exp Med; 2020 Jan; 217(1):. PubMed ID: 31821442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growth and apoptosis of human natural killer cell neoplasms: role of interleukin-2/15 signaling.
    Yamasaki S; Maeda M; Ohshima K; Kikuchi M; Otsuka T; Harada M
    Leuk Res; 2004 Oct; 28(10):1023-31. PubMed ID: 15289013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic potential of tyrosine kinase 2 in autoimmunity.
    Liang Y; Zhu Y; Xia Y; Peng H; Yang XK; Liu YY; Xu WD; Pan HF; Ye DQ
    Expert Opin Ther Targets; 2014 May; 18(5):571-80. PubMed ID: 24654603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.
    Kubo S; Yamaoka K; Kondo M; Yamagata K; Zhao J; Iwata S; Tanaka Y
    Ann Rheum Dis; 2014 Dec; 73(12):2192-8. PubMed ID: 24013646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
    Tanaka Y; Maeshima K; Yamaoka K
    Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i70-4. PubMed ID: 22460142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.